Sign up to save your podcasts
Or
Share Oncotarget
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Oncotarget
By Oncotarget PodcastScience
Oncotarget episodes
- Oncotarget: LAT1 - A Promising Anti-Cancer TargetThis week's cover paper of Oncotarget (Volume 12, Issue 13) is entitled, "Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target," by researchers from Kindai University, Higashiosaka-Shi, Osaka, Japan; Tohoku University, Sendai-Shi, Miyagi, Japan; Tokyo University of Science, Noda-shi, Chiba, Japan; Hyogo University of Health Sciences, Kobe-Shi, Hyogo, Japan.Abstract:L-type amino acid transporter 1 (LAT1)/SLC7A5 is the first identified CD98 light chain disulfide linked to the CD98 heavy chain (CD98hc/SLC3A2). LAT1 transports large neutral amino acids, including leucine, which activates mTOR, and is highly expressed in human cancers. We investigated the oncogenicity of human LAT1 introduced to NIH/3T3 cells by retrovirus infection. NIH/3T3 cell lines stably expressing human native (164C) or mutant (164S) LAT1 (naLAT1/3T3 or muLAT1/3T3, respectively) were established. We confirmed that endogenous mouse CD98hc forms a disulfide bond with exogenous human LAT1 in naLAT1/3T3, but not in muLAT1/3T3. Endogenous mouse CD98hc mRNA increased in both naNIH/3T3 and muLAT1/3T3, and a similar amount of exogenous human LAT1 protein was detected in both cell lines. Furthermore, naLAT1/3T3 and muLAT1/3T3 cell lines were evaluated for cell growth-related phenotypes (phosphorylation of ERK, cell-cycle progression) and cell malignancy-related phenotypes (anchorage-independent cell growth, tumor formation in nude mice). naLAT1/3T3 had stronger growth- and malignancy- related phenotypes than NIH/3T3 and muLAT1/3T3, suggesting the oncogenicity of native LAT1 through its interaction with CD98hc. Anti-LAT1 monoclonal antibodies significantly inhibited in vitro cell proliferation and in vivo tumor growth of naLAT1/3T3 cells in nude mice, demonstrating LAT1 to be a promising anti-cancer target.Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27981DOI - https://doi.org/10.18632/oncotarget.27981Full text - https://www.oncotarget.com/article/27981/text/Correspondence to - Takashi Masuko - [email protected]Keywords - CD98, LAT1, monoclonal antibody, NIH/3T3, oncogenicityAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetYouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnlsMedia Contact180092209576 min
- Table of Contents: Oncotarget Volume 12, Issue #13Listen to short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 13.https://www.oncotarget.com/archive/v12/i13/Cover Paper“Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target”https://doi.org/10.18632/oncotarget.27981News“A new class of radiosensitizers for glioblastoma”https://doi.org/10.18632/oncotarget.27970 (PDF Download)Research Paper“A platform for locoregional T-cell immunotherapy to control HNSCC recurrence following tumor resection”https://doi.org/10.18632/oncotarget.27982Research Paper“Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous cell carcinoma” https://doi.org/10.18632/oncotarget.27992Research Paper“Association of high-sensitivity C-reactive protein and odds of breast cancer by molecular subtype: analysis of the MEND study” https://doi.org/10.18632/oncotarget.27991Research Paper“Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells”https://doi.org/10.18632/oncotarget.27989Research Paper“TERT and its binding protein: overexpression of GABPA/B in high grade gliomas” https://doi.org/10.18632/oncotarget.27985Review“Cross-talks in colon cancer between RAGE/AGEs axis and in-flammation/immunotherapy” https://doi.org/10.18632/oncotarget.27990Review“Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors” https://doi.org/10.18632/oncotarget.27988Research Perspective“Targeting super-enhancers reprograms glioblastoma central carbon metabolism” https://doi.org/10.18632/oncotarget.27938Editorial Perspective“Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia” https://doi.org/10.18632/oncotarget.27919 (PDF Download)Editorial“The formation of pre-effectors in the steady state opens a new perspective for cancer immunosurveillance” https://doi.org/10.18632/oncotarget.27967 (PDF Download)Editorial“Mechanisms of gefitinib-induced interstitial pneumonitis: why and how the TKI perturbs innate immune systems?” https://doi.org/10.18632/oncotarget.27958 (PDF Download)Keywords - oncogenicity, glioblastoma, head and neck cancer, immunotherapy, tumors, glioma, colon cancer, epigenetics, cancer immunosurveillance, gefitinib, AML, breast cancer, cancer, science, research, oncologyAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetLinkedIn - https://www.linkedin.com/company/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/oncotargetyoutubePinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/OncotargetOncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnlsMedia Contact1800922095710 min
- Trending with Impact: Combination Therapeutics Inhibit Breast Cancer ResistanceOncotarget published this trending research paper on March 30, 2021, entitled, "Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine" by researchers from the University of Texas MD Anderson Cancer Center, Houston, Texas.Triple-negative breast cancer (TNBC) accounts for 10-15% of all breast cancers. “Triple-negative” refers to the lack of HER2 protein and estrogen and progesterone receptors. This means that TNBC cannot be treated with hormone inhibition and must be treated with conventional chemotherapy. In addition, many of these highly adaptable breast cancer cells can opportunistically switch between proliferation and quiescence. This highly-heterogeneous cancer is very difficult to treat, and TNBC patients frequently develop drug resistance and relapse after neoadjuvant therapies.The researchers from the University of Texas MD Anderson Cancer Center conducted a research study in hopes of developing a safe and effective therapeutic combination to treat resistant triple-negative breast cancer.“Evidence suggests that SUM149-metabolic adaptable (MA) cells are a suitable model of resistant human triple-negative breast cancer (TNBC) cells that can survive bottlenecks in the body, including therapeutic interventions, by opportunistically switching between quiescence and cell proliferation.”In this in vitro study, researchers cultured three highly drug-resistant and metastatic progenitor-like TNBC cell lines with a difficult phenotype—opportunistic switching between quiescence and proliferation. Researchers focused on designing a safe treatment that is effective in both low- and high-risk patients. The researchers note that it was critical to their study that the regimen is proven safe to administer to patients for early use in the minimal residual disease (MRD) stage after surgery, and before clinical metastasis is detected.“For a potential therapy to be suitable at the MRD stage, it must be safe (an important criterion prior to clinical relapse) and disrupt heterogeneous progenitor-like cancer cells that evolve into clinical metastases.”Two chemotherapy and immunosuppressive drugs (ribonucleoside analogues) were tested on the cell lines at low doses for the sake of viability in the MRD stage: 6-mercaptopurine (6-MP) and 5-azacitidine (5-AzaC). Both of these drugs have been clinically proven to be well-tolerated and to have drug-sensitizing, quiescence-stabilizing, and apoptosis-inducing effects in cancer cells.“We chose 5-AzaC because it could complement 6-MP’s effects on the transcriptome and epigenome, and—as indicated by many Phase 1 clinical trials—5-AzaC is well tolerated.”Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27922DOI - https://doi.org/10.18632/oncotarget.27922Full text - https://www.oncotarget.com/article/27922/text/Correspondence to - Anthony Lucci - [email protected] and Balraj Singh - [email protected]Keywords - resistant TNBC, minimal residual disease, intratumor heterogeneity, breast cancer relapse, metastasis preventionAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetYouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnlsMedia Contact180092209576 min
- Oncotarget: CRISPR Used in Triple Negative Breast Cancer ResearchIn this week's cover paper of Oncotarget (Volume 12, Issue 12), entitled, "Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity," researchers used the CRISPR-Cas9 tool to analyze a p53 mutation in triple-negative breast cancer.The researchers from the City University of New York, Columbia University, and Weill Cornell Medical College wrote that both the C-terminal domain (CTD) and oligomerization domain (OD) of mtp53 R273H proteins are intact, and it is not clear if these regions are responsible for chromatin-based DNA replication activities. To examine the ability of mtp53 R273H to influence cell proliferation, DNA replication, and cell cycle progression of breast cancer cells, the researchers used the CRISPR-Cas9 tool to edit the C-terminal regions of the mtp53 gene.“CRISPR-Cas9 sgRNA editing of the C-terminal regions of the endogenous mtp53 gene were carried out so as to delete gene sequences that correspond to the OD and CTD regions.”The team generated breast cancer cells and edited CTD and OD regions of mtp53 R273H using the CRISPR-Cas9 tool. They then treated the cell populations with thymidine—to block cells at G1/S phase in the cell cycle. The researchers then compared the status and proliferation of the variants with the original cell line and observed changes in total cell lysates by western blot analysis.“We examined how changes in the level of mtp53 R273H level and/or deletion of the CTD, or OD plus CTD, region influenced cell proliferation, cell cycle progression, and chromatin association of mtp53, RPA, PCNA and MCM2.”Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27975DOI - https://doi.org/10.18632/oncotarget.27975Full text - https://www.oncotarget.com/article/27975/text/Correspondence to - Jill Bargonetti - [email protected]Keywords - mutant p53, gain-of-function, oligomerization, DNA replication, frame-shift, breast cancerAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetYouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnlsMedia Contact180092209578 min
- Table of Contents: Oncotarget Volume 12, Issue #12Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 12.The full issue of Oncotarget: https://www.oncotarget.com/archive/v12/i12/COVER PAPER:“Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity”https://doi.org/10.18632/oncotarget.27975NEWS:“LY6 gene family presents a novel class of potential biomarkers associated with overall survival outcome of pancreatic ductal adenocarcinoma”https://doi.org/10.18632/oncotarget.27968 (PDF Download)EDITORIAL:“Neoantigen evolution in head and neck cancer progression: Where do we go from here?”https://doi.org/10.18632/oncotarget.27942 (PDF Download)EDITORIAL:“Unexpected zinc dependency of ferroptosis – what is in a name?” https://doi.org/10.18632/oncotarget.27951 (PDF Download)RESEARCH PAPER:“Role for Fgr and Numb in retinoic acid-induced differentiation and G0 arrest of non-APL AML cells”https://doi.org/10.18632/oncotarget.27969RESEARCH PAPER:“Dynamic cellular biomechanics in responses to chemotherapeutic drug in hypoxia probed by atomic force spectroscopy” https://doi.org/10.18632/oncotarget.27974RESEARCH PAPER:“Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type” https://doi.org/10.18632/oncotarget.27978RESEARCH PAPER:“Deep learning with deep convolutional neural network using FDG-PET/CT for malignant pleural mesothelioma diagnosis” https://doi.org/10.18632/oncotarget.27979Keywords - mutant p53, DNA replication, head and neck cancer, biomarker, ferroptosis, retinoic acid(RA), hypoxia, thymic epithelial tumor, mesothelioma, AML, breast cancer, pancreatic cancer, cancer, science, research, oncologyAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetLinkedIn - https://www.linkedin.com/company/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/oncotargetyoutubePinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/OncotargetOncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnlsMedia Contact180092209577 min
- Oncotarget: Novel Urine Protein Biomarkers In Bladder CancerOncotarget published this trending research paper on April 13, 2021, entitled, "Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens" conducted by researchers from the University of Houston and UT Southwestern Medical Center.Bladder cancer is four times more common among men than women, and it is the sixth most common cancer diagnosis in the United States. However, researchers have found that cystoscopy—the primary method physicians use to diagnose patients with bladder cancer—is relatively invasive, expensive, and has the potential to cause urinary tract infections.“In contrast, urine is a noninvasive and readily available biological fluid that can be used for diagnostic tests.”Patients may benefit in a number of different ways by using urine as fluid in diagnostic testing for bladder cancer. Urine is readily bioavailable, non-invasive, and it can also be collected and tested on a regular basis. Patients can even use various cost-effective point-of-care diagnostic tools, including at-home testing. First, the researchers assessed whether there were useful biomarkers of bladder cancer to be found in this fluid. The team used Luminex screening to test for both low and high levels of 16 proteins utilizing highly specific antibody-protein interactions.“In this study, Luminex screening was used to simultaneously assay the protein abundances of 16 potential biomarkers in different stages of bladder cancer and then compared to urology clinic controls.”ELISA validation was then used to determine which proteins were significantly elevated in bladder cancer. They found that levels of three urine proteins were capable of distinguishing between control and bladder cancer urine. One protein was also found to be capable of discriminating between high- and low-grade disease, and the successive clinical stages of bladder cancer.“Upon ELISA validation, urine IL-1α, IL-1ra, and IL-8 were able to distinguish control urine from urine drawn from various bladder cancer stages, with IL-8 being the best discriminator.”To date, the research paper has generated an Altmetric Attention Score of 55. The Altmetric Attention Score provides an at-a-glance indication of the volume and type of online attention the research has received.Top Oncotarget publications rated by Altmetric Attention Score - https://www.oncotarget.com/news/altmetric/Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27941DOI - https://doi.org/10.18632/oncotarget.27941Full text - https://www.oncotarget.com/article/27941/text/Correspondence to - Chandra Mohan - [email protected]Keywords - urothelial, proteomics, targeted screens, interleukins, inflammationAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetYouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnlsMedia Contact180092209575 min
- Oncotarget: Blood-Based Biomarker in SCCAIn this week's cover paper of Oncotarget (Volume 12, Issue 11) entitled, "CEA as a blood-based biomarker in anal cancer," researchers from The University of Texas – MD Anderson Cancer Center, Terasaki Foundation of Biomedical Sciences, and Vanderbilt Ingram Cancer Center conducted a retrospective, single-institution study to determine the correlation between carcinoembryonic antigen (CEA) levels (a commonly employed assay for patients with colorectal adenocarcinoma) and biopsy-proven Squamous cell carcinoma of the anal canal (SCCA).The researchers retrospectively analyzed 219 patients who were treated at The University of Texas – MD Anderson Cancer Center between 2013 and 2020. The team collected demographic data, clinical history, and CEA levels, including gender, ethnicity, stage at initial diagnosis of SCCA, HPV status, HIV status, and smoking history. Patients with coexisting second primary cancers besides SCCA were excluded from their analysis.The median age of patients in the study was 56 years old, 74% were female, and 89% were of Caucasian ethnicity. At the time of the initial CEA measurement, patients were at various stages of SCCA, with 39% in stage III and 41% with metastatic disease to distant organs. 67% of patients had currently or previously tested positive for HPV infection. Statistical analysis was calculated using the summarized demographic and clinical characteristics of patients as means with associated standard deviations.“Here we report the largest series detailing the relevance of CEA as a biomarker for patients with SCCA.”Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27959DOI - https://doi.org/10.18632/oncotarget.27959Full text - https://www.oncotarget.com/article/27959/text/Correspondence to - Van K. Morris - [email protected]Keywords - carcinoembryonic antigen, squamous cell carcinoma of anal canal, anal cancer, biomarkers, HPVAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetYouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnlsMedia Contact180092209576 min
- Table of Contents: Oncotarget Volume 12, Issue #11Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 11.View the complete issue: https://www.oncotarget.com/archive/v12/i11/COVER PAPER:“CEA as a blood-based biomarker in anal cancer”https://doi.org/10.18632/oncotarget.27959NEWS:“FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?”https://doi.org/10.18632/oncotarget.27957 (PDF Download)EDITORIAL:“Advances in innovative exosome-technology for real time monitoring of viable drugs in clinical translation, prognosis and treatment response”https://doi.org/10.18632/oncotarget.27927 (PDF Download)EDITORIAL:“Drug-development, dose-selection, rational combinations from bench-to-bedside: are there any lessons worth revisiting?” https://doi.org/10.18632/oncotarget.27931 (PDF Download)RESEARCH PAPER:“Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab”https://doi.org/10.18632/oncotarget.27965RESEARCH PAPER:“Caspase-11 and AIM2 inflammasome are involved in smoking-induced COPD and lung adenocarcinoma” https://doi.org/10.18632/oncotarget.27964RESEARCH PAPER:“A novel E2F1-regulated lncRNA, LAPAS1, is required for S phase progression and cell proliferation”https://doi.org/10.18632/oncotarget.27962RESEARCH PAPER:“Epigallocatechin-3-gallate modulates Tau Post-translational modifications and cytoskeletal network” https://doi.org/10.18632/oncotarget.27963RESEARCH PAPER:“Ex vivo analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma” https://doi.org/10.18632/oncotarget.27961REVIEW:“Evaluation of liver kinase B1 downstream signaling expression in various breast cancers and relapse free survival after systemic chemotherapy treatment” https://doi.org/10.18632/oncotarget.27929CASE REPORT:“Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review”https://doi.org/10.18632/oncotarget.27966Keywords - anal cancer, prostate cancer, colorectal cancer, lung cancer, breast cancer, exosomes, cell proliferation, Tau protein, Alzheimer’s disease, DNA repair, advanced squamous cell carcinoma, cancer, science, research, oncologyAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetLinkedIn - https://www.linkedin.com/company/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/oncotargetyoutubePinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/OncotargetOncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnlsMedia Contact180092209579 min
- Oncotarget Launches Special Collection on Skin CancerSkin cancer is a highly preventable cancer (in non-hereditary cases), due to a major risk factor being prolonged exposure to ultraviolet (UV) radiation. However, skin cancer is the most commonly diagnosed cancer in the United States. By the age of 70, one in five Americans are predicted to be diagnosed with skin cancer.There are three types of cells that are usually involved in skin cancer: basal cells, squamous cells, and melanocytes (or pigment producing cells). The type of skin cell affected by cancer is what classifies the difference between basal cell carcinoma, squamous cell carcinoma, and melanoma.Basal cell carcinoma is the most common and most treatable form of skin cancer. Basal cell carcinomas grow slowly and cause minimal damage if detected and treated early. The second most common form of skin cancer is squamous cell carcinoma. Squamous cell carcinoma of the skin may also be termed cutaneous squamous cell carcinoma, in order to differentiate from other squamous cell cancers that may occur in the body.Melanoma of the skin is the mutation, often followed by the rampant division, of the skin’s melanocytes. It is the most serious type of skin cancer due to its tendency to spread to other organs. Surprisingly, as much as 30% of all melanoma cases are a result of factors other* than exposure to the sun or other UV light. The causes of such cases are still unknown to researchers, but some suggest that causes could be hereditary.Oncotarget’s Special Collection on Skin Cancer & Melanoma is intended to be a tool for researchers and science readers alike to learn more about the current landscape of skin cancer. The creators of these collections are hopeful that this resource may help researchers discover new biomarkers, mechanisms, and therapies that improve our collective quality of life and lead to enhanced treatments for cancer and other diseases.Papers within this Special Collection relate to various topics on skin cancer research, including a 2018 paper from Australia on the first blood test for early detection of melanoma, a paper by researchers from Columbia University on a combined therapeutic approach that improves anti-tumor antibody therapy in melanoma, and many more.Read Oncotarget’s Special Collection on Skin Cancer: https://www.oncotarget.com/collections/skin-cancer/Visit the Special Collections Archive: https://www.oncotarget.com/collections/About OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetYouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnlsMedia Contact180092209573 min
- Trending with Impact: Role of RNA Modification Regulatory Proteins in MelanomaOncotarget published this trending research paper on June 4, 2019, entitled, “Dissecting the role of RNA modification regulatory proteins in melanoma,” by researchers from the Department of Pathology, Yale University School of Medicine, and the Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham.“Since RNA is a key molecule that drives every cellular process, their deregulation is present in nearly all human disease and play a causative role.”The researchers explain that alterations among RNAs may arise due to altered activity or expression of the enzymes/proteins which are involved in the modification process. In this study, the team used multiple publicly available bioinformatics platforms to, first, analyze RNA alterations in melanoma samples, and then, to comprehensively analyze RNA modification regulatory proteins among melanoma samples. The publicly available datasets included: The Cancer Genome Atlas, The Human Protein Atlas, Oncomine, and the UALCAN database.“Our study started with the analysis of various genetic alterations (amplifications, mutations/deletion) as well as RNA overexpression of these RNA modification regulatory proteins in The Cancer Genome Atlas melanoma database.”Based on their analyses of these databases, reverse transcription quantitative PCR, soft-agar assays, validation by shRNA-mediated knockdown, and statistical analysis, the team identified what they believe are the most relevant RNA modifying proteins that play a crucial role in the development of melanoma. They found that METTL4 and DNMT3A RNA-modifying enzymes/proteins are both necessary for melanoma growth and overexpressed in melanoma.“Based on this we infer that the upregulated expression of RNA modification regulatory proteins METTL4 and DNMT3A play a key role in melanoma initiation or progression.”Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.26959DOI - https://doi.org/10.18632/oncotarget.26959Full text - https://www.oncotarget.com/article/26959/text/Correspondence to - Romi Gupta - [email protected]Keywords - RNA modifications, epitranscriptome, melanoma, MAPK, BRAF mutant melanoma, skin cancerAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetYouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnlsMedia Contact180092209576 min
About Oncotarget
From the publisher's feed
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.
Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/